News & Press
Sooma launches direct-to-patient brain stimulation therapy in Finland and Germany
Sooma Medical12/8/2025·12/08/25🌐 Europe
Summary
Sooma Medical launched a direct-to-patient model for its tDCS therapy for depression and chronic pain in Finland and Germany, removing the need for doctor referrals. The company has treated over 30,000 patients in 250 clinics across 35 countries. Sooma received FDA approval to start a US clinical trial in March 2025.
Why it matters
Sooma's direct-to-patient model could dramatically expand access to non-invasive brain stimulation for depression, addressing strained healthcare resources and long waiting times. As the first MDR-approved tDCS system, Sooma is pioneering a new care delivery model.
#tDCS#Mental Health Tech#Depression#Europe#Industry
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trialAlready a member? Sign in